Lupus News Today Home | Lupus News Today
WEBFDA grants fast track designation to CAR T-cell therapy for SLE. The U.S. Food and Drug Administration (FDA) has granted fast track designation to Caribou Biosciences‘ CAR T-cell therapy CB-010 for systemic lupus erythematosus (SLE) — the most common form of lupus — that’s resistant to available treatments, the company announced in a ...
Phase 3 trials of ianalumab for SLE, lupus nephritis now enrolling
WEBJun 15, 2023 · All three trials are being sponsored by Novartis, the company developing ianalumab. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, recently announced that it will be teaming up with Novartis to help run these trials at sites in North America. “We believe this collaboration between Lupus Therapeutics and Novartis Pharmaceuticals will provide a significant ...
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
WEBSep 29, 2017 · New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study. “With an urgent need for a new treatment ...
Lupus overview - Lupus News Today
WEBFeb 9, 2023 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
WEBJul 24, 2023 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
1st patient enrolled in global Phase 2 trial of daxdilimab for...
WEBMay 18, 2023 · A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative lupus nephritis (LN) — a lupus complication marked by kidney damage — has enrolled its first patient.
News Archives - Lupus News Today
WEBJoint pain very common in lupus, affects patients’ life quality: Study. The vast majority of people with systemic lupus erythematosus (SLE) experience musculoskeletal symptoms, marked by pain, ache, discomfort, and numbness, often in the joints, primarily the hands, wrists, and knees. That’s according to a study from researchers in Egypt ...
Lupus Patients Often Feel Isolated, Stigmatized, Frustrated with...
WEBMay 10, 2017 · WLF Survey: Nearly Half of Lupus Patients Feel Isolated, Stigmatized and Frustrated with Treatment Options. by Ines Martins, PhD May 10, 2017. Despite progress in diagnosing and managing lupus, 43 percent of those with the disease worry about the physical inactivity and social isolation it causes, finds …
Investigational Therapy for Lupus, Lenabasum, Advances to Phase 2...
WEBApr 13, 2018 · Importantly, Phase 2 trials demonstrated that treatment with lenabasum reduces disease symptoms while being safe in patients with other autoimmune rheumatic diseases, such as cutaneous systemic sclerosis (NCT02465437) and dermatomyositis (NCT02466243).The clinical trial addressing the therapy in lupus will enroll 100 adults with active joint disease and at least moderate pain.
Advancing lupus treatments aim of new Lupus ABC consortium
WEBApr 3, 2023 · The Lupus Research Alliance (LRA) has convened a public-private consortium to bring together the U.S. Food and Drug Administration (FDA) and key stakeholders to overcome scientific hurdles in lupus and advance new personalized treatments. The patient-focused Lupus Accelerating Breakthroughs Consortium …
Skip to content